These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 11169601)
41. Expected epidemiological impact of the introduction of a partially effective HIV vaccine among men who have sex with men in Australia. Gray RT; Ghaus MH; Hoare A; Wilson DP Vaccine; 2011 Aug; 29(36):6125-9. PubMed ID: 21703320 [TBL] [Abstract][Full Text] [Related]
42. Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Burton DR; Desrosiers RC; Doms RW; Feinberg MB; Gallo RC; Hahn B; Hoxie JA; Hunter E; Korber B; Landay A; Lederman MM; Lieberman J; McCune JM; Moore JP; Nathanson N; Picker L; Richman D; Rinaldo C; Stevenson M; Watkins DI; Wolinsky SM; Zack JA Science; 2004 Jan; 303(5656):316. PubMed ID: 14726576 [No Abstract] [Full Text] [Related]
43. Statistical evaluation of HIV vaccines in early clinical trials. Moodie Z; Rossini AJ; Hudgens MG; Gilbert PB; Self SG; Russell ND Contemp Clin Trials; 2006 Apr; 27(2):147-60. PubMed ID: 16426900 [TBL] [Abstract][Full Text] [Related]
44. Potential contribution of gut microbiota and systemic inflammation on HIV vaccine effectiveness and vaccine design. Routy JP; Mehraj V AIDS Res Ther; 2017 Sep; 14(1):48. PubMed ID: 28893288 [TBL] [Abstract][Full Text] [Related]
46. CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participants. Dommaraju K; Kijak G; Carlson JM; Larsen BB; Tovanabutra S; Geraghty DE; Deng W; Maust BS; Edlefsen PT; Sanders-Buell E; Ratto-Kim S; deSouza MS; Rerks-Ngarm S; Nitayaphan S; Pitisuttihum P; Kaewkungwal J; O'Connell RJ; Robb ML; Michael NL; Mullins JI; Kim JH; Rolland M PLoS One; 2014; 9(10):e111334. PubMed ID: 25350851 [TBL] [Abstract][Full Text] [Related]
47. The HIV vaccine pipeline, from preclinical to phase III. Schultz AM; Bradac JA AIDS; 2001; 15 Suppl 5():S147-58. PubMed ID: 11816163 [No Abstract] [Full Text] [Related]
48. AIDS vaccine: efficacy, safety and ethics. Veljkovic V; Veljkovic N; Glisic S; Ho MW Vaccine; 2008 Jun; 26(24):3072-7. PubMed ID: 18164521 [TBL] [Abstract][Full Text] [Related]
49. Vaccination with the Conserved Caveolin-1 Binding Motif in Human Immunodeficiency Virus Type 1 Glycoprotein gp41 Delays the Onset of Viral Infection and Provides Partial Protection in Simian/Human Immunodeficiency Virus-Challenged Cynomolgus Macaques. Hovanessian AG; Soundaramourty C; Benferhat R; Le Grand R; Dereuddre-Bosquet N; Krust B; Estaquier J J Virol; 2018 Sep; 92(18):. PubMed ID: 29976675 [TBL] [Abstract][Full Text] [Related]
50. A comparison of full-length glycoprotein 120 from incident HIV type 1 subtype E and B infections in Bangkok injecting drug users with prototype E and B strains that are components of a candidate vaccine. Phan KO; Callahan ME; Vanichseni S; Hu DJ; Raktham S; Young N; Choopanya K; Mastro TD; Subbarao S AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1445-50. PubMed ID: 11018864 [TBL] [Abstract][Full Text] [Related]
51. Screening and evaluation of potential volunteers for a phase III trial in Thailand of a candidate preventive HIV vaccine (RV148). Ministry of Public Health-Thai AIDS Vaccine Evaluation Group Vaccine; 2011 Jun; 29(25):4285-92. PubMed ID: 21435408 [TBL] [Abstract][Full Text] [Related]
52. Modeling HIV vaccine trials of the future. Gilbert PB; Huang Y; Janes HE Curr Opin HIV AIDS; 2016 Nov; 11(6):620-627. PubMed ID: 27662407 [TBL] [Abstract][Full Text] [Related]
53. HIV vaccine efficacy trials: towards the future of HIV prevention. Kim D; Elizaga M; Duerr A Infect Dis Clin North Am; 2007 Mar; 21(1):201-17, x. PubMed ID: 17502236 [TBL] [Abstract][Full Text] [Related]
54. On the analysis of viral load endpoints in HIV vaccine trials. Hudgens MG; Hoering A; Self SG Stat Med; 2003 Jul; 22(14):2281-98. PubMed ID: 12854093 [TBL] [Abstract][Full Text] [Related]
55. HIV vaccine development at the turn of the 21st century. Girard MP; Plotkin SA Curr Opin HIV AIDS; 2012 Jan; 7(1):4-9. PubMed ID: 22156840 [TBL] [Abstract][Full Text] [Related]
56. Assessing HIV vaccine effects. Koopman JS; Little RJ Am J Epidemiol; 1995 Nov; 142(10):1113-20. PubMed ID: 7485056 [TBL] [Abstract][Full Text] [Related]
57. Estimating cumulative probabilities from incomplete longitudinal binary responses with application to HIV vaccine trials. Hudgens MG Stat Med; 2003 Feb; 22(3):463-79. PubMed ID: 12529875 [TBL] [Abstract][Full Text] [Related]
58. Pox-Protein Public Private Partnership program and upcoming HIV vaccine efficacy trials. Russell ND; Marovich MA Curr Opin HIV AIDS; 2016 Nov; 11(6):614-619. PubMed ID: 27636503 [TBL] [Abstract][Full Text] [Related]
59. The aftermath of the Merck's HIV vaccine trial. Iaccino E; Schiavone M; Fiume G; Quinto I; Scala G Retrovirology; 2008 Jul; 5():56. PubMed ID: 18597681 [TBL] [Abstract][Full Text] [Related]
60. Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand. Celentano DD; Beyrer C; Natpratan C; Eiumtrakul S; Sussman L; Renzullo PO; Khamboonruang C; Nelson KE AIDS; 1995 Sep; 9(9):1079-83. PubMed ID: 8527082 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]